Luis Calderón – General Manager, Alexion Mexico
Mexico is improving its regulatory framework for orphan drugs. The general manager of Alexion Mexico explains how the company is working with the authorities to ensure adequate regulation is put…
Alexion is a global biopharmaceutical company that combines groundbreaking science with a steadfast commitment to meeting the needs of patients living with severe, life-threatening and often ultra-rare diseases. Alexion scientists are among the first in the world to unlock the therapeutic potential of inhibiting terminal complement, a group of proteins that play an important role in the body’s immune response and can destroy healthy tissue in certain patients. Alexion discovered and developed Soliris® (eculizumab), a first-in-class terminal complement inhibitor, approved in the United States, Canada, European Union, Australia, and Japan as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH). Alexion is working urgently to investigate Soliris and additional biopharmaceuticals as treatments for patients with other rare and severe diseases, including cancer.
Contact details
Alexion
Paseo de los Tamarindos 90
Torre 1 Piso 6 Oficina A
Col. Bosque de la Lomas, Del. Cuajimalpa,
C.P. 05120, México DF
MEXICO
Tel: +52 (55) 5047 1500
Website: http://alxn.com/
Mexico is improving its regulatory framework for orphan drugs. The general manager of Alexion Mexico explains how the company is working with the authorities to ensure adequate regulation is put…
Alejandro Luna and José Alfredo Sedano, lawyers at the leading legal firm of Santamarina y Steta, discuss the current legal challenges faced by companies in the pharmaceutical and healthcare sector…
The general manager in charge of Mexico, Central America and the Caribbean is on board with the corporate mission of doubling Shire’s product sales to USD 10 billion by 2020…
In the Mexican pharmaceutical industry change is the name of the game. The general director of Pierre Fabre Mexico and Central America expands on how the company has adapted its…
The general director of the National Institute for Psychiatry discusses the Institute’s commitment to translating clinical research into better care for patients, the social stigma patients with mental disorders still…
Johannes Hauser, managing director of the German-Mexican Chamber of Commerce explains the role of the chamber in Mexico and encourages small and medium-sized companies in Germany to consider the country…
Oscar Parra, general manager at Lundbeck Mexico, explains the seriousness of CNS diseases in increasingly urbanized countries and the impact they can have on the productivity of the Mexican workforce.…
The first woman appointed as general director of one of the leading neurosciences institutions in Latin America discusses the Institute’s priorities in terms of R&D for brain diseases, training of…
Probiomed wants to move to the next level. The recently appointed general director discusses her plans to grow the business and expand internationally, leveraging the company’s in-house developed biotech products…
Genomic medicine is gaining momentum. The general director of the institute founded in 2004 explains how genomics is helping unlocking the secret codes, which will help understand and treat pathologies…
For 40 years Apotex has made providing patients around the globe with access to quality and affordable medicines its priority. The general director for Northern Latin America discusses the importance…
Rodrigo Iturralde, general manager of Randall, walks us through the new plans of the company after a year of difficult yet enriching challenges and the ambitious goals set with an…
Healthcare coverage has gone a long way in Mexico after the implementation of the Seguro Popular in 2004 and today 57.3 million Mexicans are affiliated to the public health insurance…
See our Cookie Privacy Policy Here
